Top

Orphanet Journal of Rare Diseases

Published in:

Open Access 01-12-2018 | Research

Estrogen is involved in hemangioma regression associated with mast cells

Authors: Fang Hou, Yuemeng Dai, Chun-Yang Fan, James Y. Suen, Gresham T. Richter

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Abstract

Background

Estrogen plays a role in infantile hemangioma (IH) development, but the underlying mechanism remains unclear. This study aimed to assess estrogen and estrogen receptor (ER) localization and expression levels in IH. In addition, the unexpected relationship between mast cells (MCs) and estrogen in human IH was discussed.

Methods

IH (n = 29), vascular malformation (VMs, n = 33) and normal skin (n = 15) specimens were assessed. IH was classified into proliferative (n = 9; age, 3.56 ± 1.01 months), early involuting (n = 10; age, 8.90 ± 2.69 months) and late involuting (n = 10; age, 20.10 ± 4.93 months) groups. Estradiol (E2), ER-a, ER-β, and tryptase (MC marker) levels were determined immunohistochemically and/or by double immunofluorescence staining. Quantification and localization of tryptase, ER-a, and E2 were assessed for each specimen.

Results

ER-a, E2, and tryptase were expressed in the cytoplasm and nucleus of MCs in IH. The IH specimens showed significantly more tryptase, ER-a, and E2 positive MCs (30.6 ± 12.7, 9.7 ± 5.6, and 19.8 ± 8.7 cells/high-power field [HPF], respectively) compared with VM specimens (9.0 ± 9.8, 1.5 ± 2.4, and 2.5 ± 4.1 cells/HPF, respectively) and normal skin (6.1 ± 8.5, 0.5 ± 1.2, and 1.9 ± 3.4 cells/HPF, respectively). Proliferating IH displayed fewer E2 positive MCs (14.0 6.3 cells/HPF) compared with early (22.3 ± 10.2 cells/HPF, P = 0.023) and late (22.4 ± 6.8 cells/HPF, P = 0.006) involuting specimens. In addition, proliferating IH showed fewer tryptase positive MCs (24.7 ± 10.8 cells/HPF) compared with early involuting specimens (35.7 ± 15.3 cells/HPF, P = 0.043). All IH specimens were ER-a positive and ER-β negative.

Conclusions

E2 and ER-a are expressed on MCs and not on IH endothelial cells. Furthermore, activated MCs may be involved in IH regression.

Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;1:85–94.CrossRef

Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, Alió AB, Ritter M, Friedlander DF, Catanzarite V, Mendoza A, Smith L, Friedlander M, Friedlander SF. Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Br J Dermatol. 2014;170:907–13.CrossRef

Mulliken JB, Bischoff J. Pathogenesis of infantile hemangioma. In: Mulliken JB, Burrows PE, Fishman SJ, editors. Vascular anomalies: hemangiomas and malformations. 2nd ed. New York: Oxford University Press; 2013. p. 43–67.CrossRef

Tan ST, Hasan Q, Velickovic M, Ruger BM, Davis RP, Davis PF. A novel in vitro human model of hemangioma. Mod Pathol. 2000;13:92–9.CrossRef

Darrow DH, Greene AK, Mancini AJ, Nopper AJ, Section On Dermatology, Section On Otolaryngology–Head And Neck Surgery, And Section On Plastic Surgery. Diagnosis and Management of Infantile Hemangioma. Pediatrics. 2015;136:e1060–104.CrossRef

Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol. 2002;138:1567–76.CrossRef

Sasaki GH, Pang CY, Wittliff JL. Pathogenesis and treatment of infant skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. Plast Reconstr Surg. 1984;73:359–70.CrossRef

Sun ZY, Yang L, Yi CG, Zhao H, Han DL, Yang T, Wang L, Nie CL, Zhang GY, Yin GQ, Wang G, Teng XP, Fei DM, Wang J, Zhou WK, Li Y, Liu B, Liu Y, Zhang MJ, Wu SM, Zhang X, Pan H, Xiao B, Zhao KF, Liu D, Guo SZ. Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. Med Hypotheses. 2008;71:286–92.CrossRef

Zaitsu M, Narita S, Lambert KC, Grady JJ, Estes DM, Curran EM, Brooks EG, Watson CS, Goldblum RM, Midoro-Horiuti T. Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx. Mol Immunol. 2007;44:1977–85.CrossRef

10.

Jensen F, Woudwyk M, Teles A, Woidacki K, Taran F, Costa S, Malfertheiner SF, Zenclussen AC. Estradiol and progesterone regulate the migration of mast cells from the periphery to the uterus and induce their maturation and degranulation. PLoS One. 2010;5:e14409.CrossRef

11.

Harnish DC, Albert LM, Leathurby Y, Eckert AM, Ciarletta A, Kasaian M, Keith JJ. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2004;286:118–25.CrossRef

12.

Tan ST, Wallis RA, He Y, Davis PF. Mast cells and hemangioma. Plast Reconstr Surg. 2004;113:999–1011.CrossRef

13.

Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends Mol Med. 2013;19:197–209.CrossRef

14.

Reggiani BL, Boselli F, Lupi M, Bettelli S, Schirosi L, Bigiani N, Sartori G, Rivasi F. Expression of estrogen receptor in hemangioma of the uterine cervix: reports of three cases and review of the literature. Arch Gynecol Obstet. 2009;280:469–72.CrossRef

15.

Lui W, Zhang S, Hu T, Wei F, Gao Y, Cheng N. Sex hormone receptors of hemangiomas in children. Chin Med J. 1997;110:349–51.PubMed

16.

Itinteang T, Tan ST, Jia J, Steel R, Laing EL, Brasch HD, Day DJ. Mast cells in infantile haemangioma possess a primitive myeloid phenotype. J Clin Pathol. 2013;66:597–600.CrossRef

17.

Steel R, Day D. Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. Pathology. 2014;46:496–500.CrossRef

18.

Tan ST, Velickovic M, Ruger BM, Davis PF. Cellular and extracellular markers of hemangioma. Plast Reconstr Surg. 2000;106:529–38.CrossRef

19.

Hasan Q, Ruger BM, Tan ST, Gush J, Davis PF. Clusterin/apoJ expression during the development of hemangioma. Hum Pathol. 2000;31:691–7.CrossRef

20.

Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunol Rev. 2007;217:141–54.CrossRef

21.

Bosquiazzo VL, Ramos JG, Varayoud J, Munoz-de-Toro M, Luque EH. Mast cell degranulation in rat uterine cervix during pregnancy correlates with expression of vascular endothelial growth factor mRNA and angiogenesis. Reproduction. 2007;133:1045–55.CrossRef

22.

Norrby K. Mast cells and angiogenesis. APMIS. 2002;110:355–71.CrossRef

23.

Lee BS, Stewart EA, Sahakian M, Nowak RA. Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol. 1998;40:19–25.CrossRef

24.

Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, Gliksman M, Goy A, Suh KS. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7:44735–62.CrossRef

25.

Qin Y, Zhang C. The regulatory role of IFN-gamma on the proliferation and differentiation of hematopoietic stem and progenitor cells. Stem Cell Rev. 2017. https://doi.org/10.1007/s1201501797611.

26.

Itinteang T, Withers AH, Davis PF, Tan ST. Biology of infantile hemangioma. Front Surg. 2014;1:38.CrossRef

27.

Jonker L. TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets. Microcirculation. 2014;21:93–103.CrossRef

28.

Dethlefsen SM, Mulliken JB, Glowacki J. An ultrastructural study of mast cell interactions in hemangiomas. Ultrastruct Pathol. 1986;10:175–83.CrossRef

29.

Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105:117–20.CrossRef

30.

Mulliken JB. Treatment of cutaneous hemangiomas. In: Mulliken JB, Burrows PE, Fishman SJ, editors. Vascular anomalies: hemangiomas and malformations. 2nd ed. New York: Oxford University Press; 2013. p. 182–259.CrossRef

Title: Estrogen is involved in hemangioma regression associated with mast cells
Authors: Fang Hou
Yuemeng Dai
Chun-Yang Fan
James Y. Suen
Gresham T. Richter
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-018-0928-x

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Estrogen is involved in hemangioma regression associated with mast cells

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study

Nerve ultrasound characterizes AMN polyneuropathy as inhomogeneous and focal hypertrophic

Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study

Hypermanganesemia due to mutations in SLC39A14: further insights into Mn deposition in the central nervous system

Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study

Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases